AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03869736 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: 1-hour sessions of inhaled oxygen-air mixture (inspired oxygen concentration \~23-30%) to be administered weekly for 4 weeks.
Study NCT00878358 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrotherapy
Study NCT04107012 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Orthodontic treatment with clear aligner
Description: Included orthodontic treatment with clear aligner (eon Aligners)
Study NCT04107012 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Orthodontic treatment with clear aligner
Description: Included orthodontic treatment with clear aligner (eon Aligners)
Study NCT01466114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: estriol
Description: 4 capsules of 2 mg (total of 8 mg) PO QD
Study NCT01466114 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 capsules PO QD
Study NCT01466114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norethindrone
Description: Starting at month 6, and at Months 9 and 12: subjects who are on estriol (Group A) take 0.7 mg PO QD for 2 weeks.
Study NCT00878358 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapy
Study NCT05125120 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: COGNİTİVE ORİENTATİTON DAİLY OCCUPATİONAL PERFORMANCE APPROACH
Description: Polatajko et al. (2001) developed the CO-OP approach, which is an occupation-oriented problem-solving approach that combines cognitive strategies to help children acquire motor abilities throughout daily tasks (9, 29). The CO-OP approach of therapy focuses on the goal or task at hand rather than the acquisition of functions in occupational performance. CO-OP is a 'deductive' or 'occupational performance-oriented' approach that focuses on the activity target selected throughout the therapy, as opposed to 'inductive' or 'impairment-focused' alternatives (13). As a verbal approach, CO-OP focuses on skill acquisition at the activity level and strives to provide children with global problem-solving skills. Necessary performance strategies specific to the child and the activity are determined with a customised programme (12, 30). Skill acquisition, cognitive strategy development, and adapting and transferring these acquired skills to daily life are the three key goals of the approach.
Study NCT01466114 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Progestin Placebo
Description: Starting at Month 6 and at Months 9 and 12: subjects who are on placebo (Group B) take a second progestin placebo pill PO QD for 2 weeks.
Study NCT02620865 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given SC
Study NCT02620865 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Antibody Therapy
Description: Given anti-CD3 x anti-EGFR-bispecific antibody armed activated T-cells IV
Study NCT04299633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vadadustat
Description: 2 x 150 mg oral tablets
Study NCT04299633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sevelamer carbonate
Description: 2 x 800 mg oral tablets
Study NCT04299633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcium acetate
Description: 2 x 667 mg oral gelcaps
Study NCT04299633 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Auryxia®
Description: 2 x 1 gram tablets (210 mg ferric iron equivalent to 1000 mg ferric citrate)
Study NCT01410591 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 8-mm covered stent group
Description: Creating a shunt between hepatic vein and portal vein with a 8-mm covered stent by TIPS procedure.
Study NCT01410591 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: 10-mm covered stent group
Description: Creating a shunt between hepatic vein and portal vein with a 10-mm covered stent by TIPS procedure.
Study NCT01375114 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panax Ginseng
Description: 400 mg by mouth twice daily from Day 1-29.
Study NCT01702012 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Almased Meal Replacement Powder
Description: Commercially available meal replacement product that contains soy protein, honey, yogurt, and amino acids. Participants assigned to this arm will receive the Almased meal replacement product and will be asked to replace one meal per day during the first 6 month. During the second 6 months, they will be allowed to choose to continue using the Almased as a meal replacement or to use it as a supplement prior to meals.
Study NCT01702012 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Group-Based Lifestyle Intervention
Study NCT02962635 — intervention group
Intervention type: DEVICE
Intervention: bioelectrical impedance measurement and biomarker measurement
Description: Measuring volume status with bioelectrical impedance measurement and comparing with biomarker level
Study NCT04441931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3832479
Description: Administered IV.
Study NCT04441931 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered IV.
Study NCT05441969 — intervention group
Intervention type: OTHER
Intervention: No intervention/expousure
Description: No interventions/expousure since this is an observational study.
Study NCT01837082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ferric carboxymaltose
Study NCT01837082 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04211545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rabeprazole
Description: Rabeprazole
Study NCT04211545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CC-92480
Description: CC-92480
Study NCT01375114 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by mouth twice daily for 4 weeks.
Study NCT01375114 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Questionnaires
Description: Completion of questionnaires taking about 30 minutes on Day 15 (± 3 days), Day 29 (± 3 days), and Day 57 (± 3 days), regarding symptoms such as fatigue, mood, depression, anxiety, nausea, appetite problems, sleep problems, and overall sense of well-being.
Study NCT04509700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Parsaclisib
Description: Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib as that provided in the parent Protocol at the time of the rollover.
Study NCT04509700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parsaclisib + itacitinib
Description: Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 100 mg of itacitinib as that provided in the parent Protocol at the time of the rollover.
Study NCT04509700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parsaclisib + ruxolitinib
Description: Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and the same dose of ruxolitinib that was provided in the parent Protocol at the time of the rollover.
Study NCT04509700 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: parsaclisib + ibrutinib
Description: Participants will continue on the same dose (1,2.5,5 OR 20 mg) and schedule of parsaclisib and 140 mg of ibrutinib as that provided in the parent Protocol at the time of the rollover.
Study NCT01735110 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: transfemoral intervention (TFI)
Study NCT01735110 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transradial intervention
Study NCT02749487 — intervention group
Intervention type: OTHER
Intervention: Neutrophil Lymphocyte Ratio
Description: Neutrophil:lymphocyte ratio (NLR) is an emerging biomarker that is used to predict mortality and morbidity. The association of this biomarker with systemic illness and its usefulness in risk assessment of critically ill patients has not been fully elucidated.
Study NCT04363307 — intervention group
Intervention type: DEVICE
Intervention: AF Ablation
Description: Adult participants undergoing standard of care AF ablation using VISITAG SURPOINT
Study NCT04363307 — intervention group
Intervention type: DEVICE
Intervention: MRI
Description: Adult participants will undergo a late gadolinium enhancement MRI of the left atrium three months post standard of care ablation
Study NCT02620865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluorouracil
Description: Given IV
Study NCT02620865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine Hydrochloride
Description: Given IV
Study NCT02620865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan Hydrochloride
Description: Given IV
Study NCT02620865 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01011205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Advagraf
Description: Capsule
Study NCT01011205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mycophenolate Mofetil
Description: Solution for infusion
Study NCT01011205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Basiliximab
Description: IV infusion
Study NCT02620865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin Calcium
Description: Given IV
Study NCT02620865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Given IV
Study NCT02620865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel Albumin-Stabilized Nanoparticle Formulation
Description: Given IV
Study NCT02620865 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Sargramostim
Description: Given SC
Study NCT02099591 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naloxegol
Description: Opioid Antagonist
Study NCT01011205 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Corticosteroids
Description: IV bolus
Study NCT04329949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant, 100 mg and 25 mg
Description: Relacorilant is supplied as capsules for oral dosing.
Study NCT04329949 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nab-paclitaxel
Description: Nab-paclitaxel is administered as IV infusion over 30 minutes on Days 1, 8, and 15 of each 28-day cycle.
Study NCT01375114 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Questionnaires
Description: Completion of questionnaires taking about 30 minutes on Day 15 (± 3 days), Day 29 (± 3 days), and Day 57 (± 3 days), regarding symptoms such as fatigue, mood, depression, anxiety, nausea, appetite problems, sleep problems, and overall sense of well-being.
Study NCT02182037 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single rising doses of BIBT 1011 BS
Study NCT02182037 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: BIBT 1011 BS placebo
Study NCT01115023 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: iron cooking pot
Description: the mother was instructed to cook the family food in the iron cooking pot for the study period (60 days) as frequently in the day as possible.
Study NCT04619342 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: GSMs-TACE
Description: TACE using epirubicin (30-40mg/m2) and gelatin sponge microspheres (150-350μm or 350-560μm)
Study NCT04619342 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GSMs-TACE
Description: TACE using epirubicin (30-40mg/m2) and gelatin sponge microspheres (150-350μm or 350-560μm)
Study NCT04619342 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical Resection
Description: Surgical Resection of PVTT
Study NCT03631329 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Doppler sonographic measurement
Description: First, place a 4.5-12.0 MHz linear array transducer vertically on the neck with the probe marker facing the patient's head. A long axis B-mode image of the right common carotid artery is obtained at the lower border of the thyroid cartilage. The sample volume is then placed in the center of the lumen located approximately 2 cm proximal to the carotid bifurcation. Next, pulsed wave Doppler tracing is performed in the arterial blood flow. The cycle time using the calliper function in an ultrasonic machine is obtained by measuring the interval between heartbeats at the beginning of the Doppler blood flow upstroke and the Flow time is measured as the time from the beginning of the systolic upstroke to the dicrotic notch.
Study NCT04002323 — intervention group
Intervention type: DRUG
Intervention: Dolutegravir 50mg Tab
Description: The subjects starts their ART with this drugs, once a day
Study NCT04002323 — intervention group
Intervention type: DRUG
Intervention: Lamivudine 300 mg
Description: The subjects starts their ART with this drugs, once a day
Study NCT00784069 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lactic Acid
Description: Lactic Acid (Dermacyd Breeze)
Study NCT02825953 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: surfactant
Description: the investigators attempt to administer surfactant in a more gentle way, i.e. by nebulization, by minimally invasive surfactant therapy, and endotracheal bolus application of natural surfactant
Study NCT02825953 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: nasal continuous positive airway pressure
Description: each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). The infants will be stabilised on NCPAP (Neopuff; Fisher and Paykel, Auckland, New Zealand) in the delivery room and during transport to the NICU. NCPAP or NIPPV will be started within 30 min of birth immediately after randomisation. Both NCPAP and NIPPV will be delivered by a neonatal ventilator (Engström Carestation; GE Healthcare, Madison, USA) via short, binasal Cannula (RAM Cannula; Neotech, Valencia, CA).
Study NCT02825953 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: non-invasive intermittent positive-pressure ventilation
Description: each infant will be randomly assigned to nasal continuous positive airway pressure (NCPAP) or non-invasive intermittent positive-pressure ventilation (NIPPV). The infants will be stabilised on NCPAP (Neopuff; Fisher and Paykel, Auckland, New Zealand) in the delivery room and during transport to the NICU. NCPAP or NIPPV will be started within 30 min of birth immediately after randomisation. Both NCPAP and NIPPV will be delivered by a neonatal ventilator (Engström Carestation; GE Healthcare, Madison, USA) via short, binasal Cannula (RAM Cannula; Neotech, Valencia, CA).
Study NCT00683553 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: I5NP
Description: Single IV injection of experimental drug given in escalated doses at 0.5, 1.5, 5.0 and 10 mg/kg doses to different patients
Study NCT00683553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: I5NP
Description: Single IV injection of experimental drug given in escalated doses at 0.5, 1.5, 5.0 and 10 mg/kg doses to different patients
Study NCT00683553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Single IV injection of saline
Study NCT03825042 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: A mix of bioactive natural compounds
Description: A mix of bacopa, lycopene, astaxanthin and vitamin B12 in oral tablets
Study NCT03825042 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Inactive compound in oral tablets
Study NCT03305211 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: sample
Description: Participation in NephroMIC involves additional blood samples of 5 tubes (35 mL) and an additional sample of fresh urine.
Study NCT03841877 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: endodontic treatment
Description: The operator will remove the pulp inside the tooth, clean, disinfect and shaping the root canals and seal the space with endodontic sealer.
Study NCT00821821 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MCI-186
Description: Cohort 1: Edaravone: circa 1000 mg / 72-hour infusion~Cohort 2: Edaravone: circa 2000 mg / 72-hour infusion
Study NCT00821821 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Cohort1:circa 1000mg / 72-hour infusion matching placebo~Cohort2:circa 2000mg / 72-hour infusion matching placebo
Study NCT00379483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Study NCT02764866 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep testing
Description: Home sleep testing
Study NCT00077181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cytarabine
Description: Given IV
Study NCT03780322 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Armeo Spring Pediatric
Description: Before intervention, the robotic device will be adjusted to the user's unique dimensions to avoid injury.~Each 45 minute session will include active upper extremity shoulder abduction, shoulder external rotation and/or elbow extension exercises, led by virtual reality game and supported by robotic arm. Sessions will take place 3 times a week for a total of 15 sessions.
Study NCT03780322 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional physical and occupational therapy
Description: Conventional therapy will combine physical and occupational therapy, including the following activities:~1. Upper extremity weight bearing exercises.~2. Approximation techniques on wrist, elbow and shoulder.~3. Proprioceptive neuromuscular facilitation: shoulder flection, adduction and external rotation and shoulder flection, abduction and external rotation.~4. Scapulothoracic joint mobilization.~5. Stretching of shoulder abductors and external rotators.~6. Hand/wrist facilitation exercises (with ball). This will be carried out in 45 minute sessions, 3 times a week, for a total of 15 sessions.
Study NCT00077181 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: triapine
Description: Given IV
Study NCT00077181 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT04044547 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rotigotine, extended-release microspheres
Description: Four stable dose levels of LY03003 at 14, 28, 42 and 56 mg will be evaluated. For each dose level, the stable dose will be administered once a week for consecutive 5 weeks. To improve patient's tolerability, dose upward titration will be applied to 28, 42 and 56 mg dose groups according to the following schedule:~* Patients to be enrolled to 14 mg dose group will receive 14 mg for 5 consecutive weeks.~* Patients to be enrolled to 28 mg dose group will receive 14 mg in the first week and then 28 mg in the next 5 weeks.~* Patients to be enrolled to 42 mg dose group will receive 14 mg in the first week, 28 mg in the second week and then 42 mg in the next 5 weeks.~* Patients to be enrolled to 56 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week and then 56 mg in the next 5 weeks.
Study NCT04044547 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo, extended-release microspheres
Description: Four stable dose levels of placebo at 14, 28, 42 and 56 mg will be evaluated. For each dose level, the stable dose will be administered once a week for consecutive 5 weeks. To improve patient's tolerability, dose upward titration will be applied to 28, 42 and 56 mg dose groups according to the following schedule:~* Patients to be enrolled to 14 mg dose group will receive 14 mg for 5 consecutive weeks.~* Patients to be enrolled to 28 mg dose group will receive 14 mg in the first week and then 28 mg in the next 5 weeks.~* Patients to be enrolled to 42 mg dose group will receive 14 mg in the first week, 28 mg in the second week and then 42 mg in the next 5 weeks.~* Patients to be enrolled to 56 mg dose group will receive 14 mg in the first week, 28 mg in the second week, 42 mg in the third week and then 56 mg in the next 5 weeks.
Study NCT02825953 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neopuff
Description: Fisher and Paykel, Auckland, New Zealand
Study NCT02825953 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: neonatal ventilator
Description: GE Healthcare, Madison, USA
Study NCT01916369 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTX DP
Description: Single dose treatment consisting of 10 injections (20, 50 or 80 million cells) into the gastrocnemius muscle near to the damaged area
Study NCT00964678 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Description: twice daily oral treatment in escalating dose
Study NCT03033693 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Bispectral index will be targeted at 50
Description: The depth of general anesthesia will be monitored by bispectral index (BIS) at 50.
Study NCT03033693 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Bispectral index will be targeted at 35
Description: The depth of general anesthesia will be monitored by bispectral index (BIS) at 35.
Study NCT03000114 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Needle Aponeurotomy
Study NCT03000114 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: XIAFLEX